Key facts
- It has raised $300K; the latest was Early Stage VC ($3.4M) in Mar 2025.
- Notable investors include Venture Kick, Kickfund, Venture (Switzerland).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Amporin
- ·The full record, as it builds
Funding rounds
No funding rounds for Amporin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amporin
Developer of a novel class of small-molecule drugs designed to stop, reverse, and effectively cure chronic degenerative diseases linked to protein misfolding and aggregation. The company offers unique pore inhibitors that disrupt and repair holes in cell and mitochondrial membranes caused by misfolded protein oligomers, enabling patients with conditions like Alzheimer's, Parkinson's, Huntington's disease, ALS, and type II diabetes to recover and restore cellular homeostasis.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Employees
- 3
- Website
- amporin.com/
- Ownership
- Privately Held (backing)
Amporin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amporin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amporin in its N-PORT filings yet. We sweep new filings monthly.